-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Upgrades Summit Therapeutics to Market Perform, Raises Price Target to $13

Benzinga·08/12/2026 18:22:49
Listen to the news
Leerink Partners analyst Daina Graybosch upgrades Summit Therapeutics (NASDAQ:SMMT) from Underperform to Market Perform and raises the price target from $12 to $13.